Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB9LRJ)

• Drug Name: Bintrafusp alfa Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMB9LRJ

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[3]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[3]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[4]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[5]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[8]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[11]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[12]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[13]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[14]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[15]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[16]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[19]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[2]
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [2] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [5] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [6] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Agenus.
• [8] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [9] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [10] Clinical pipeline report, company report or official report of Roche
• [11] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [14] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [17] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [18] National Cancer Institute Drug Dictionary (drug id 740856).
• [19] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [20] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.